Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Carisma Therapeutics Doses First Patient In Phase 1 Clinical Trial Of CT-0525, A Novel HER2-Targeting CAR-Monocyte

Author: Benzinga Newsdesk | May 16, 2024 07:43am

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting

Initial data expected by year-end 2024

Posted In: CARM